Emicizumab treatment in chronic intermittent haemodialysis

Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review

“…[ 69 ] 2020 31 (≥65 y) With and without Nine fatalities were reported, none of which were related to emicizumab N/A Case studies Weise et al. [ 70 ] 2022 1 (64 y) N/A Emicizumab was well tolerated Patient was undergoing chronic intermittent hemodialysis. Emicizumab was efficacious; plasma levels remained stable throughout hemodialysis Nonsevere hemophilia A Clinical trials Hermans et al.…”

“…The report included 9 fatalities; however, none were reported as related to emicizumab. One case report described the use of emicizumab in a 64-year-old male with severe hemophilia A undergoing chronic intermittent hemodialysis; emicizumab was well tolerated and efficacious, and plasma levels remained stable throughout hemodialysis [ 70 ].…”